Peter X. Shaw
- Immunology top 0.5%
- Atherosclerosis and Cardiovascular Diseases 24
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms 12
- Biochemistry top 1%
- Immunology and Allergy top 2%
- Rheumatology top 1%
- Systemic Lupus Erythematosus Research 6
- Ophthalmology top 1%
- Retinal Diseases and Treatments 11
-
- Retinal Development and Disorders 9
- Inflammasome and immune disorders 7
-
- Cerebrovascular and Carotid Artery Diseases 6
-
- Adipokines, Inflammation, and Metabolic Diseases 5
- Co-authors
- Joseph L. WitztumMi-Kyung ChangChristoph J. BinderSohvi HörkköWulf PalinskiKarsten HartvigsenGregg J. SilvermanYury I. Miller
- Journals
- Circulation (3 papers)Oxidative Medicine and Cellular Longevity (3 papers)Nature Medicine (2 papers)
- Partner nations
- United StatesChinaAustria
In The Last Decade
Peter X. Shaw
55 papers receiving 5.1k citations
Hit Papers
Peers
Comparison fields: 5 of 114
- Immunology 3.2k
- Biochemistry 484
- Immunology and Allergy 344
- Rheumatology 659
- Ophthalmology 394
Countries citing papers authored by Peter X. Shaw
This map shows the geographic impact of Peter X. Shaw's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter X. Shaw with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter X. Shaw more than expected).
Fields of papers citing papers by Peter X. Shaw
This network shows the impact of papers produced by Peter X. Shaw. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter X. Shaw. The network helps show where Peter X. Shaw may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Peter X. Shaw, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2021 | 14 | |
| 3 | 2021 | 15 | |
| 4 | 2018 | 115 | |
| 5 | 2017 | 10 | |
| 6 | 2016 | 52 | |
| 7 | 2015 | 10 | |
| 8 | A Novel Compound Heterozygous Mutation in the BEST1 Gene Causes Autosomal Recessive Best Vitelliform Macular Dystrophy | 2012 | 1 |
| 9 | 2011 | 91 | |
| 10 | 2010 | 24 | |
| 11 | 2010 | 34 | |
| 12 | 2009 | 365 | |
| 13 | 2008 | 135 | |
| 14 | 2008 | 112 | |
| 15 | 2008 | 32 | |
| 16 | 2007 | 10 | |
| 17 | 2003 | 139 | |
| 18 | 2003 | 91 | |
| 19 | Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDLbreakdown → | 2003 | 590 |
| 20 | 2000 | 16 |
About Peter X. Shaw
Peter X. Shaw is a scholar working on Ophthalmology, Immunology, Developmental Neuroscience, Biochemistry and Aging, having authored 55 papers that have together received 5.2k indexed citations. Recurring topics across this work include Atherosclerosis and Cardiovascular Diseases (24 papers), Neutrophil, Myeloperoxidase and Oxidative Mechanisms (12 papers), Retinal Diseases and Treatments (11 papers), Retinal Development and Disorders (9 papers), Inflammasome and immune disorders (7 papers), Systemic Lupus Erythematosus Research (6 papers), Cerebrovascular and Carotid Artery Diseases (6 papers) and Adipokines, Inflammation, and Metabolic Diseases (5 papers). The work is most often cited by research in Immunology (3.2k citations), Biochemistry (484 citations), Immunology and Allergy (344 citations), Rheumatology (659 citations) and Ophthalmology (394 citations). Peter X. Shaw has collaborated with scholars based in United States, China and Austria. Frequent co-authors include Joseph L. Witztum, Mi-Kyung Chang, Christoph J. Binder, Sohvi Hörkkö, Wulf Palinski, Karsten Hartvigsen, Gregg J. Silverman, Yury I. Miller, Asheesh K. Dewan and Sotirios Tsimikas. Their work appears in journals such as Circulation, Oxidative Medicine and Cellular Longevity, Nature Medicine, Journal of Clinical Investigation and Experimental Eye Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.